| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.974 auroc unitless · higher Uncertainty: 95% CI 0.9641 to 0.9834 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C18; group 'BRCA'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.941 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.9220 to 0.9600 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E18; group 'BRCA'; row 'end'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.862 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8305 to 0.8942 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D18; group 'BRCA'; row 'end'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.969 auroc unitless · higher Uncertainty: 95% CI 0.9596 to 0.9788 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C28; group 'CHOL'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.853 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8055 to 0.9012 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E28; group 'CHOL'; row 'end'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.75 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.6867 to 0.8133 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D28; group 'CHOL'; row 'end'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.975 auroc unitless · higher Uncertainty: 95% CI 0.9665 to 0.9837 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C38; group 'CRC'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.885 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8432 to 0.9268 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E38; group 'CRC'; row 'end'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.843 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.7956 to 0.8911 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D38; group 'CRC'; row 'end'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2)
Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024) | 0.966 auroc unitless · higher Uncertainty: 95% CI 0.9580 to 0.9748 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Jiang cohort liver cancer cross-validation ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C88; group 'LIHC'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.999 auroc unitless · higher Uncertainty: 95% CI 0.9971 to 1.0000 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C58; group 'NSCLC'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 1 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 1.0000 to 1.0000 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E58; group 'NSCLC'; row 'end'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.97 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9366 to 1.0000 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D58; group 'NSCLC'; row 'end'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.999 auroc unitless · higher Uncertainty: 95% CI 0.9978 to 0.9997 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C68; group 'OV'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 1 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 1.0000 to 1.0000 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E68; group 'OV'; row 'end'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.973 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.9533 to 0.9933 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D68; group 'OV'; row 'end'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.837 auroc unitless · higher Uncertainty: 95% CI 0.8058 to 0.8680 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C78; group 'PAAD'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.717 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.6658 to 0.7675 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E78; group 'PAAD'; row 'end'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.598 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.5398 to 0.6568 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D78; group 'PAAD'; row 'end'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.964 auroc unitless · higher Uncertainty: 95% CI 0.9586 to 0.9692 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C8; group 'PANCAN'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.963 auroc unitless · higher Uncertainty: 95% CI 0.9442 to 0.9810 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C48; group 'STAD'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.927 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.8959 to 0.9574 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E48; group 'STAD'; row 'end'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.87 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.8285 to 0.9115 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D48; group 'STAD'; row 'end'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.733 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C18; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'end'; column 'AUC' |
|---|
| Configuration: Fragment endpoint counts, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.504 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceend (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E18; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'end'; column 'Sensitivity @85% specificity' |
|---|